Abstract | OBJECTIVE: DESIGN: Ten normoglycemic, normolipemic patients affected with psoriasis vulgaris were studied before and after 1 and 3 months of oral treatment with 35 microg of acitretin. METHODS: RESULTS: One-month acitretin treatment reduced psoriasis activity, insulin sensitivity, evaluated as QUICKI values (0.364 +/- 0.034 versus 0.329 +/- 0.051; P < 0.05) and HOMA-IR index (1.53 +/- 0.73 versus 2.59 +/- 1.41; P < 0.05), and high-density lipoprotein ( HDL)-cholesterol levels (45.2 +/- 11.7 versus 39.4 +/- 10.4 mg/dl; P = 0.01). The impairment in glucose and lipid homeostasis was transient and not associated to BMI variations. Adiponectin levels did not change during the treatment, while resistin levels, which were higher in untreated patients than in controls (9.4 +/- 4.4 versus 6.2 +/- 2.1 ng/ml; P = 0.05), fell within the normal range after 1 and 3 months of therapy. The normalization of resistin levels occurred without significant changes in circulating tumor necrosis factor alpha ( TNFalpha) levels, which persisted elevated throughout the treatment. CONCLUSIONS:
|
Authors | S Corbetta, R Angioni, A Cattaneo, P Beck-Peccoz, A Spada |
Journal | European journal of endocrinology
(Eur J Endocrinol)
Vol. 154
Issue 1
Pg. 83-6
(Jan 2006)
ISSN: 0804-4643 [Print] England |
PMID | 16381995
(Publication Type: Journal Article)
|
Chemical References |
- Adiponectin
- Blood Glucose
- Cholesterol, HDL
- Lipids
- Resistin
- Acitretin
|
Topics |
- Acitretin
(therapeutic use)
- Adiponectin
(blood)
- Adult
- Blood Glucose
(metabolism)
- Cholesterol, HDL
(blood)
- Cohort Studies
- Humans
- Insulin Resistance
(physiology)
- Lipids
(blood)
- Male
- Middle Aged
- Prospective Studies
- Psoriasis
(drug therapy)
- Resistin
(blood)
|